Abnormal neuroendocrine response to clomipramine in hereditary affective psychosis

Depression and Anxiety

Volumn 26, Issue 8, 2009, Pages

  Cordes, Joachim ^a   Larisch, Rolf ^a   Henning, Uwe ^a   Thünker, Johanna ^a   Werner, Christian ^a   Orozco, Guillermo ^b   Mayoral, Fermín ^b   Rivas, Fabio ^b   Auburger, Georg ^a   Tosch, Marco ^a   Rietschel, Marcella ^c   Gaebel, Wolfgang ^a   Müller, Hans Wilhelm ^a   Klimke, Ansgar ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Affective disorder; Challenge; Cortisol; Depression; Prolactin; Response

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CLOMIPRAMINE; CLOZAPINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE DECANOATE; FLURAZEPAM; HALOPERIDOL; HYDROCORTISONE; IMIPRAMINE; LITHIUM; LORAZEPAM; PAROXETINE; PROLACTIN; SERTRALINE; SULPIRIDE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC DISORDER; HAMILTON SCALE; HORMONAL REGULATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR AFFECTIVE DISORDER; MALE; NAUSEA; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RADIOIMMUNOASSAY; RECURRENT BRIEF DEPRESSION; REMISSION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIPOLAR DISORDER; CLOMIPRAMINE; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PROLACTIN; REFERENCE VALUES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; YOUNG ADULT;

EID: 68149134870     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20405     Document Type: Article

References (53)

1. Ginns EI, Ott J, Egeland JA, Allen CR, Fann CSJ, Pauls DL, Weissenbachoff J, Carulli JP, Falls KM, Keith TP, Paul SM. A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish. Nat Genet 1996;12:431-435. (Pubitemid 26105936)
2. Blackwood DHR, He L, Morris SW, McLean A, Whitton C, Thomson M,Walker MT,Woodburn K, Sharp CM, Booij L, van der Does AJ, Haffmans PM, Spinhoven P, Mc Nally RJ. Acute tryptophan depletion as a model of depressive relapse: behavioural specificity and ethical considerations. Br J Psychiatry 2005;187:148-154. (Pubitemid 41139687)
3. Gurling H, Smyth C, Kalsi G, Moloney E, Rifkin L, O'Neill J, Murphy P, Curtis D, Petursson H, Bruynjolfsson J. Linkage findings in bipolar disorders. Nat Genet 1995;10:8-9.
4. Pekkarinen P, Terwilliger J, Bredbacka PE, Lonnqvist J, Peltonen L. Evidence of a predisposing locus to bipolar disorder on Xq24-q27.1 in an extended Finnish pedigree. Genome Res 1995;5:105-115.
5. Freimer NB, Reus VI, Escamilla MA, McInnes A, Spesny M, Leon P, Service SK, Smith LB, Silva S, Rojas E, Gallegos A, Meza L, Fournier E, Baharloo S, Blankenship K, Tyler DJ, Batki S, Vinogradov S, Weissenbach J, Barondes SH, Sandkuijl LA. Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. Nat Genet 1996;12:436-441.
6. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press Ltd; 1995.
7. Moeller O, Norra C, Gründer G. Monoaminergic function in major depression. A possibly helpful tool for choosing treatment strategy. Der Nervenazt 2006;77:800-808.
8. Booij L, Van der Does W, Benkelfat C, Bremner JD, Cowen PJ, Fava M, Gillin C, Leyton M, Moore P, Smith KA, Van der Kloot WA. Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology 2002;27:852-861. (Pubitemid 35335901)
9. Klaassen T, Riedel WJ, Deutz NE, van Someren A, van Praag HM. Specificity of the tryptophan depletion method. Psychopharmacology (Berl) 1999;141:279-286.
10. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418. (Pubitemid 20161259)
11. Van der Does AJ. The effects of tryptophan depletion on mood and psychiatric symptoms. J Affect Disord 2001;64:107-119. Review.
12. Sobczak S, Honig A, Schmitt JA, Riedel WJ. Pronounced cognitive deficits following an intravenous L-tryptophan challenge in first-degree relatives of bipolar patients compared to healthy controls. Neuropsychopharmacology 2003;28:711-719.
13. Booij L, Van der Does AJ, Haffmans PM, Riedel WJ. Acute tryptophan depletion in depressed patients treated with a selective serotonin-noradrenalin reuptake inhibitor: augmentation of antidepressant response? J Affect Disord 2005;86:305-311.
14. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35:837-844. (Pubitemid 9076798)
15. Lichtenberg P, Shapira B, Gillon D, Kindler S, Cooper TB, Newman ME, Lerer B. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res 1992;43:137-146.
16. Lopez-Ibor Jr. JJ, Saiz-Ruiz J, Iglesias LM. The fenfluramine challenge test in the affective spectrum: a possible marker of endogeneity and severity. Pharmacopsychiatry 1988;21:9-14. (Pubitemid 18073874)
17. Siever LJ, Murphy DL, Sater S, de la Vega E, Lipper S. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sci 1984;34:1029-1039.
18. Sobczak S, Honig A, van Duinen MA, Riedel WJ. Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disord 2002;4:347-456. (Pubitemid 36041464)
19. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996;153:174-182. (Pubitemid 26038957)
20. Golden RN, Ekstrom D, Brown TM, Ruegg R, Evans DL, Haggerty Jr. JJ, Garbutt JC, Pedersen CA, Mason GA, Browne J, Carson SW. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry 1992;149:1168-1175.
21. Cowen PJ, Charig EM. Neuroendocrine responses to intravenous tryptophan in major depression. Arch Gen Psychiatry 1987;44:958-966.
22. Deakin JF, Pennell I, Upadhyaya AJ, Lofthouse R. A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology (Berl) 1990;101:85-92. (Pubitemid 20124747)
23. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-295. Review. (Pubitemid 13255331)
24. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ. The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab 1989;68:632-637. (Pubitemid 19081440)
25. Golden RN, Hsiao JK, Lane E, Ekstrom D, Rogers S, Hicks R, Potter WZ. Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients. Psychiatry Res 1990;31:39-47. (Pubitemid 20049543)
26. 18F]altanserin binding to 5HT2 receptors in man. Behav Brain Res 2003;139:21-29.
27. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994;51:687-697.
28. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, Allilaire JF, Feingold J, Mallet J, Malafosse. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry 1998;55:33-37.
29. Gerra G, Caccavari R, Zaimovic A, Palladino M, Chittolini B, Giucastro G, Maestri D, Monica C, Fertonani-Affini G, Delsignore R, Brambilla F. Serotonergic function in mothers of opioid addicts: correlation with comorbid depression. Acta Psychiatr Scand 1997;96:36-42. (Pubitemid 27323710)
30. Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology (Berl) 2000;150:120-122. (Pubitemid 30350822)
31. Flory JD, Mann JJ, Manuck SB, Muldoon MF. Recovery from major depression is not associated with normalization of serotonergic function. Biol Psychiatry 1998;43:320-326.
32. Shapira B, Cohen J, Newman ME, Lerer B. Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biol Psychiatry 1993;33:531-535. (Pubitemid 23167220)
33. Upadhyaya Ak, Pennell I, Cowen PJ, Deakin JF. Blunted growth hormone and prolactin responses to L-tryptophan in depression: a state dependent abnormality. J Affect Disord 1991;21:213-218.
34. Kasper S, Vieira A, Schmidt R, Richter P. Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment. Pharmacopsychiatry 1990;23:76-84. (Pubitemid 20159956)
35. O'Keane V, McLoughlin D, Dinan TG. D-fenfluramine induced prolactin and cortisol release in major depression: response to treatment. J Affect Disord 1992;26:143-150.
36. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in patients with affective and personality disorders. Correlation with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587-599.
37. Mannuzza S, Fyer AJ, Endicott J, Klein DF. Family informant schedule and criteria (FISC). New York: Anxiety Disorders Clinic, New York State Psychiatric Institute; 1985.
38. SAS Institute Inc. SAS/STAT® User's Guide, Version 8. Cary, NC: SAS Institute Inc; 1999.
39. Thompson JM, Gallagher P, Hughes JH, Watson S, Gray JM, Ferrier IN, Young AH. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005;186:32-40. (Pubitemid 40070541)
40. Cleare AJ, Murray RM, O'Keane V. Assessment of serotonergic function in major depression using d-fenfluramine: relation to clinical variables and antidepressant response. Biol Psychiatry 1998;44:555-561. (Pubitemid 28496682)
41. Golden RN, Heine AD, Ekstrom RD, Bebchuk JM, Leatherman ME, Garbutt JC. A longitudinal study of serotonergic function in depression. Neuropsychopharmacology 2002;26:653-659. (Pubitemid 34260984)
42. Monteleone P, La Rocca A, Fuschino A, Bortolotti F, Maj M. Seasonal variation in plasma prolactin response to D-fenfluramine in healthy subjects. Psychoneuroendocrinology 1999;24:201-208. (Pubitemid 29125351)
43. Kavoussi RJ, Hauger RL, Coccaro EF. Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors. Biol Psychiatry 1999;45:295-299. (Pubitemid 29100034)
44. O'Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991;148:1009-1015.
45. Cleare AJ, Murray RM, O'Keane V. Do noradrenergic reuptake inhibitors affect serotonergic function in depression? Psychopharmacology (Berl) 1997;134:406-410.
46. Sargent PA, Williamson DJ, Cowen PJ. Brain 5-HT neurotransmission during paroxetine treatment. Br J Psychiatry 1998;172:49-52.
47. 2 receptors. Psychopharmacology (Berl) 1998;140:120-122.
48. Thakore JH, O'Keane V, Dinan TG. D-fenfluramine-induced prolactin responses in mania: evidence for serotonergic subsensitivity. Am J Psychiatry 1996;153:1460-1463. (Pubitemid 26365462)
49. Meltzer HY, Perline R, Tricou BJ, Lowy M, Robertson A. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. Arch Gen Psychiatry 1984;42:379-387.
50. FitzGerald M, Malone K, Li S, Suckow R, Mann JJ. Plasma tryptophan levels and prolactin response to fenfluramine in healthy volunteers. Biol Psychiatry 1997;42:416-418. (Pubitemid 27380976)
51. Oquendo MA, Placidi GP, Malone KM, Campbell C, Keilp J, Brodsky B, Kegeles LS, Cooper TB, Parsey RV, van Heertum RL, Mann JJ. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatry 2003;60:14-22. (Pubitemid 36070860)
52. Kegeles LS, Malone KM, Slifstein M, Ellis SP, Xanthopoulos E, Keilp JG, Campbell C, Oquendo M, Van heertum RL, Mann JJ. Response of cortical metabolic deficits to serotonergic challenge in familial mood disorders. Am J Psychiatry 2003;160:76-82. (Pubitemid 36042429)
53. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-889.